Cerus

Cerus

Biotechnology Research

Concord, California 9,169 followers

At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe.

About us

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Website
http://www.cerus.com
Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Concord, California
Type
Public Company
Founded
1992
Specialties
blood safety, pathogen inactivation, hospital safety, patient safety, pandemic preparedness, plasma, pathogen reduction, blood supply, healthcare, public health, transfusion medicine, platelets, and bleeding

Locations

Employees at Cerus

Updates

Affiliated pages

Similar pages

Browse jobs

Stock

CERS

NASDAQ

20 minutes delay

$2.36

0.105 (4.667%)

Open
2.3
Low
2.265
High
2.39

Data from Refinitiv

See more info on Bing